The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...
The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...
MISSION, Kan., Aug. 4, 2025 /PRNewswire/ -- (Family Features) If you're the one tracking medications, scheduling appointments and making sure the whole household stays...
Presentation highlights Blacksmith's novel chemistry platform for targeting metalloenzymes and FG-2101, a first-in-class non-hydroxamate LpxC inhibitor
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Blacksmith Medicines,...
TORONTO, July 31, 2025 /CNW/ - Bayshore HealthCare (Bayshore) is proud to announce its Integrated Care Solutions (ICS) division has achieved Accredited with Commendation...
Schlage electrified mortise locks broaden application opportunities with quiet control solutions.
CARMEL, Ind., July 29, 2025 /PRNewswire/ -- Allegion US, a leading provider of security solutions, technology and...
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1
DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...
DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...